Key clinical point: A combination of immunostimulating agents showed early efficacy against refractory cancers.
Major finding: Two of five patients with stage IV melanoma had partial responses and significant tumor shrinkage.
Study details: An ongoing, phase Ib/2 safety and dose-escalation trial.
Disclosures: The REVEAL study is supported by Nektar Therapeutics. Dr. Diab reported institutional research funding, consulting fees, and advisory board participation from Nektar, Bristol-Myers Squib, Idera Pharmaceuticals, Jounce Therapeutics, and Array BioPharma.
Diab A et al. ASCO-SITC,.